Gilead Sciences, Inc. (TSX:GILD)

Market Cap	208.78B
Revenue (ttm)	40.51B
Net Income (ttm)	11.30B
Shares Out	n/a
EPS (ttm)	8.95
PE Ratio	18.48
Forward PE	14.06
Dividend	0.16 (0.65%)
Ex-Dividend Date	Dec 15, 2025

Volume	11,694
Average Volume	2,956
Open	24.83
Previous Close	24.73
Day's Range	24.58 - 25.28
52-Week Range	20.08 - 26.29
Beta	n/a
RSI	50.47
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD